| Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical … TA Rasmussen, M Tolstrup, CR Brinkmann, R Olesen, C Erikstrup, ... The lancet HIV 1 (1), e13-e21, 2014 | 685 | 2014 |
| The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo OS Søgaard, ME Graversen, S Leth, R Olesen, CR Brinkmann, SK Nissen, ... PLoS pathogens 11 (9), e1005142, 2015 | 576 | 2015 |
| Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity M Hoffmann, H Hofmann-Winkler, JC Smith, N Krüger, P Arora, ... EBioMedicine 65, 2021 | 329 | 2021 |
| Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation TA Rasmussen, OS Søgaard, C Brinkmann, F Wightman, SR Lewin, ... Human vaccines & immunotherapeutics 9 (5), 993-1001, 2013 | 250 | 2013 |
| Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase … S Leth, MH Schleimann, SK Nissen, JF Højen, R Olesen, ME Graversen, ... The lancet HIV 3 (10), e463-e472, 2016 | 198 | 2016 |
| Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting B Julg, L Dee, J Ananworanich, DH Barouch, K Bar, M Caskey, DJ Colby, ... The lancet HIV 6 (4), e259-e268, 2019 | 173 | 2019 |
| Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission—a randomized trial KB Kristoffersen, OS Søgaard, C Wejse, FT Black, T Greve, B Tarp, ... Clinical Microbiology and Infection 15 (5), 481-487, 2009 | 173 | 2009 |
| Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. JD Gunst, NB Staerke, MH Pahus, LH Kristensen, J Bodilsen, N Lohse, ... EClinicalMedicine 35, 2021 | 172 | 2021 |
| Short-course toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection L Vibholm, MH Schleimann, JF Højen, T Benfield, R Offersen, ... Clinical Infectious Diseases 64 (12), 1686-1695, 2017 | 154 | 2017 |
| SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses LK Vibholm, SSF Nielsen, MH Pahus, GS Frattari, R Olesen, R Andersen, ... EBioMedicine 64, 2021 | 146 | 2021 |
| Camostat mesylate against SARS‐CoV‐2 and COVID‐19—Rationale, dosing and safety P Breining, AL Frølund, JF Højen, JD Gunst, NB Staerke, E Saedder, ... Basic & clinical pharmacology & toxicology 128 (2), 204-212, 2021 | 139 | 2021 |
| Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial OS Søgaard, N Lohse, ZB Harboe, R Offersen, AR Bukh, HL Davis, ... Clinical infectious diseases 51 (1), 42-50, 2010 | 125 | 2010 |
| A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells R Offersen, SK Nissen, TA Rasmussen, L Østergaard, PW Denton, ... Journal of virology 90 (9), 4441-4453, 2016 | 115 | 2016 |
| HIV reactivation from latency after treatment interruption occurs on average every 5-8 days—implications for HIV remission M Pinkevych, D Cromer, M Tolstrup, AJ Grimm, DA Cooper, SR Lewin, ... PLoS pathogens 11 (7), e1005000, 2015 | 112 | 2015 |
| Reversal of latency as part of a cure for HIV-1 TA Rasmussen, M Tolstrup, OS Søgaard Trends in microbiology 24 (2), 90-97, 2016 | 104 | 2016 |
| Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial L Toft, M Storgaard, M Müller, P Sehr, J Bonde, M Tolstrup, L Østergaard, ... The Journal of infectious diseases 209 (8), 1165-1173, 2014 | 103 | 2014 |
| Broad activation of latent HIV-1 in vivo K Barton, B Hiener, A Winckelmann, TA Rasmussen, W Shao, K Byth, ... Nature communications 7 (1), 12731, 2016 | 92 | 2016 |
| Innate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostat R Olesen, S Vigano, TA Rasmussen, OS Søgaard, Z Ouyang, M Buzon, ... Journal of virology 89 (20), 10176-10189, 2015 | 92 | 2015 |
| SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity SSF Nielsen, LK Vibholm, I Monrad, R Olesen, GS Frattari, MH Pahus, ... EBioMedicine 68, 2021 | 88 | 2021 |
| The effectiveness of pneumococcal polysaccharide vaccination in HIV‐infected adults: a systematic review RH Pedersen, N Lohse, L Østergaard, OS Søgaard HIV medicine 12 (6), 323-333, 2011 | 88 | 2011 |
